Sharemaestro Newsreel

Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance

Shares in Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) rallied 25% in premarket trading on Friday, driven by a solid quarterly print and 2026 revenue forecast, which the company said would exceed $145M while targeting adjusted EBITDA margin above 35%. Chief executive officer Sean Brynjelsen said the …

Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35%

Earnings Call Insights: Eton Pharmaceuticals (ETON) Q2 2026 MANAGEMENT VIEW * CEO Sean Brynjelsen said the company delivered “record revenue, significant margin expansion and important progress across both our commercial portfolio and pipeline,” while also completing “several strategic transactions” intended to support long-term growth. …

5 Must-Read Analyst Questions From Elanco’s Q2 Earnings Call

5 Must-Read Analyst Questions From Elanco's Q2 Earnings Call Elanco's results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, …

Eton Pharmaceuticals Q2 2026 Earnings Call Transcript

United Therapeutics CEO Rothblatt sells $4.89m in stock

What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders

Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings

Amneal Pharmaceuticals director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on August 11, 2026. The shares were sold at a weighted average price of $17.18, with individual trades ranging from $17.07 to $17.31. Following this …

Kaplan Fox is Investigating Hims & Hers Health, Inc. (NYSE: HIMS) for Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. This investigation follows a lawsuit filed by the FTC and California/Utah authorities alleging that Hims & Hers failed to clearly disclose prescription charges, made it …

ETON PHARMACEUTICALS ($ETON) Releases Q2 2026 Earnings, Stock Rises

Eton Pharmaceuticals earnings beat by $0.28, revenue topped estimates

Eton Pharmaceuticals (ETON) reported Q2 earnings of $0.35 per share, significantly beating the Zacks Consensus Estimate of $0.11, and revenues of $37.59 million, surpassing estimates by 38.12%. Despite strong financial performance and a 145.9% stock increase year-to-date, the company currently holds a Zacks Rank …

HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook

HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter's revenue guidance ($890 …

Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS

Farallon group (LNTH) discloses 5.58M-share, 8.6% position in Lantheus

Farallon Capital Management, L.L.C. and its related funds have reported a beneficial ownership of 5,583,479 shares of Lantheus Holdings, Inc. common stock, which represents 8.6% of the outstanding class as of June 30, 2026. This disclosure was made via an amended Schedule 13G filing. …

Eton Pharmaceuticals soars 25% on earnings beat, raised guidance

Eton Pharmaceuticals (NASDAQ:ETON) shares surged 25% after reporting strong second-quarter results that significantly exceeded analyst expectations. The company posted adjusted EPS of $0.43 and revenue of $37.6 million, driven by HEMANGEOL sales and growth in its rare disease portfolio. Eton also raised its full-year …

Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades

Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, sold a total of 216,613 shares of Class A Common Stock in two separate transactions on August 11 and August 12, 2026. The sales were open-market transactions, not pursuant to a Rule 10b5-1 trading …

Eton Pharmaceuticals (NASDAQ: ETON) swings to H1 2026 profit on revenue jump

Eton Pharmaceuticals (NASDAQ: ETON) reported a significant financial turnaround, swinging to a profit in the first half of 2026 with net income of $13.1 million, compared to a net loss of $4.1 million in the same period of 2025. This improvement was driven by …

Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and …

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

Eton Pharmaceuticals reported record Q2 2026 product sales of $37.6 million, a 99% increase year-over-year, and raised its full-year revenue guidance to over $145 million. The company's strong performance was driven by the successful relaunch of HEMANGEOL and growth across its rare disease portfolio, …

Eton Now Expects 2026 Revenue to Exceed $145M After Q2

Eton Pharmaceuticals reported strong Q2 2026 financial results, with net revenue surging 99% year-over-year to $37.6 million. Driven by the successful relaunch of HEMANGEOL and growth across its rare disease portfolio, the company has raised its full-year 2026 revenue guidance to exceed $145 million …

Centrum Reframes Healthy Aging as a Proactive Practice for Adults 35 and Beyond

With the introduction of Centrum Age Defy alongside the trusted Centrum Silver portfolio, Centrum is helping redefine healthy aging as a lifelong journey, not a destination. Key Takeaways Centrum, the #1 doctor- and pharmacist-recommended multivitamin brand, is helping redefine healthy aging as a proactive, …

Michael Burry Sends Fresh AI Warning on Nebius, Micron and Oracle

This article first appeared on GuruFocus. Michael Burry (Trades, Portfolio) has increased bearish positions tied to artificial intelligence and semiconductor stocks, while adding to selected long holdings, according to a Wednesday Substack post. Warning! GuruFocus has detected 3 Warning Signs with MU. Is MU …

Indivior Pharmaceuticals, Inc. (INDV) Options Chain

This article provides the options chain for Indivior Pharmaceuticals, Inc. (INDV), listing both call and put options with their respective strike prices, last trade dates, prices, and other relevant data. It includes current stock performance and related pharmaceutical tickers.

Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?

Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own …

Viatris (VTRS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- …

Can Asceniv Help ADMA Stock Combat IG Market Challenges?

ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous – slra 10% liquid) …

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia Corporation LQDA reported second-quarter 2026 earnings per share (EPS) of 74 cents, which topped the Zacks Consensus Estimate of 70 cents. In the year-ago quarter, the company reported a loss per share of 49 cents. Total revenues surged to $171.7 million from $8.8 …

Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat

Liquidia reported a strong second quarter, with total revenue of $171.7 million, exceeding Wall Street estimates, largely driven by sales of its inhaled lung disease drug, Yutrepia. Since its launch in June 2025, Yutrepia has received approximately 5,900 unique patient prescriptions and contributed significantly …

United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings

Liquidia: YUTREPIA Reaches 5,000+ Patients As Inhaled Prostacyclin Market Expands Nearly 40%

Liquidia's YUTREPIA has reached over 5,000 patients and generated $170.4 million in Q2 net product sales, contributing to a nearly 40% expansion of the inhaled prostacyclin market since its launch. The company has seen four consecutive quarters of increasing profitability and is pursuing a …

LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path

Liquidia Corporation's Q2 2026 earnings call emphasized the growth of YUTREPIA, aiming for over $1 billion in net revenue by 2027 through commercial expansion and increased adoption. The company reported strong Q2 financial results, with EPS and revenues exceeding consensus estimates, and plans to …

Takeda Pharmaceutical (TAK) executive reports sale of 20,363 ADS at $17.55

Shannon Elaine Mary, President of Global Supply & Quality at Takeda Pharmaceutical Co. Ltd. (TAK), sold 20,363 American Depositary Shares (ADS) at a price of $17.55 per ADS on August 11, 2026. This transaction was an open market or private sale, and after the …

Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 165,393 Shares of Stock

Andrew Stewart Plump, an insider at Takeda Pharmaceutical (NYSE:TAK), sold 165,393 shares of the company's stock for approximately $2.83 million. This sale was conducted to cover tax obligations from vested equity awards, reducing his stake by 17.75%. Despite mixed analyst ratings, with a consensus …

Takeda (TAK) President IBU sells 31,083 ADSs in tax-related transaction

Giles Richard Platford, President, IBU of Takeda Pharmaceutical Co Ltd (TAK), sold 31,083 American Depositary Shares (ADSs) on August 10, 2026, at a weighted average price of $17.10 per share. This transaction was a mandatory sale to cover taxes associated with the vesting of …